The blood brain barrier (BBB), a layer of tightly packed cells that prevents viruses and toxins from entering the brain, makes neurodegenerative disorders, neuropsychiatric diseases and brain tumors uniquely challenges to diagnose and treat. Patients typically have exceptionally short times to live once their brain diseases are able to be diagnosed using MRI technology since the structure of brain or BBB has been disrupted dramatically at that time. To respond to this problem, it is essential to develop early diagnosis and treatment options.
PET/SPECT imaging technology could realize the noninvasive in vivo neuroimaging via the small molecules labeled with radioisotope, which were called PET/SPECT tracers. We would like to develop some novel PET/SPECT tracers with high binding affinity and specificity to the targets including receptors, enzyme, ion channels et al. to diagnose brain disease as early as possible. Treatment of brain disease is also a difficult problem due to that blood-brain-barrier (BBB) prevents most of the small molecules (drugs) from entering the brain. Thus, if we would like to use drug to cure the brain disease the first problem we need to settle is making the drug cross the BBB. Our strategy is using nanoparticle with functional group to help drug cross the BBB.
The scope of the Research Topic includes the development of PET/SPECT/MRI imaging agents and functionalized nanoparticle.
• diagnosis of brain diseases including cancers,
• neurodegenerative and neuropsychiatric disorders using imaging agents,
• treatment by nanoparticles. We are interested in all of manuscripts relating to these two themes.
The blood brain barrier (BBB), a layer of tightly packed cells that prevents viruses and toxins from entering the brain, makes neurodegenerative disorders, neuropsychiatric diseases and brain tumors uniquely challenges to diagnose and treat. Patients typically have exceptionally short times to live once their brain diseases are able to be diagnosed using MRI technology since the structure of brain or BBB has been disrupted dramatically at that time. To respond to this problem, it is essential to develop early diagnosis and treatment options.
PET/SPECT imaging technology could realize the noninvasive in vivo neuroimaging via the small molecules labeled with radioisotope, which were called PET/SPECT tracers. We would like to develop some novel PET/SPECT tracers with high binding affinity and specificity to the targets including receptors, enzyme, ion channels et al. to diagnose brain disease as early as possible. Treatment of brain disease is also a difficult problem due to that blood-brain-barrier (BBB) prevents most of the small molecules (drugs) from entering the brain. Thus, if we would like to use drug to cure the brain disease the first problem we need to settle is making the drug cross the BBB. Our strategy is using nanoparticle with functional group to help drug cross the BBB.
The scope of the Research Topic includes the development of PET/SPECT/MRI imaging agents and functionalized nanoparticle.
• diagnosis of brain diseases including cancers,
• neurodegenerative and neuropsychiatric disorders using imaging agents,
• treatment by nanoparticles. We are interested in all of manuscripts relating to these two themes.
